Haryana govt order for athletes to deposit 1/3rd share of their earnings sparks a row

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Chennai, Jun 10: DMK MLA J Anbazhagan who had tested positive for coronavirus and was on ventilator support from June 3 passed away at a hospital in Chennai on Wednesday.

Coincidently, today is the 62nd birthday of the MLA.

"Anbazhagan J, who has been fighting for his life with severe COVID 19 pneumonia rapidly deteriorated early this morning. In spite of full medical support including mechanical ventilation at our COVID facility, he succumbed to his illness. He was declared dead at 08:05 hours on the 10th of June 2020," the hospital said in a statement.

In 2001, Anbazhagan was elected from T Nagar Assembly constituency. He served for five years.

Later in 2011, he was elected to Tamil Nadu Assembly from Chepauk-Thiruvallikeni seat. The DMK leader was re-elected from the same constituency in 2016.

New Delhi, Jul 6: India's cricket chief Sourav Ganguly says improved fitness standards and a change in culture have led to the country developing one of the world's best pace attacks.

Spearheads Mohammed Shami and Jasprit Bumrah are part of a battery of five formidable quick bowlers that have helped change India's traditional reliance on spin bowling.

"You know culture has changed in India that we can be good fast bowlers," Ganguly said in a chat hosted on the Board of Control for Cricket in India (BCCI) Twitter feed.

"Fitness regimes, fitness standards not only just among fast bowlers but also among the batters, that has changed enormously. That has made everyone understand and believe that we are fit, we are strong and we can also bowl fast like the others did."

The West Indies dominated world cricket in the 1970s and 1980s led by a fearsome pace attack that included all-time greats such as Michael Holding, Andy Roberts, Malcolm Marshall and Joel Garner.

Recently Indian quicks have risen to the top in world cricket with Shami, Bumrah, Ishant Sharma, Umesh Yadav and Bhuvneshwar Kumar in a deadly arsenal.

"The West Indies in my generation were naturally strong," the former India captain said.

"We Indians were never such naturally strong... but we worked hard to get strong. But I think it is the change in culture as well that is very important."

Shami last month claimed that the current Indian pace attack may be the best in Test history.

"You and everyone else in the world will agree to this -- that no team has ever had five fast bowlers together as a package," said Shami.

"Not just now, in the history of cricket, this might be the best fast-bowling unit in the world."

Shami took 13 wickets during India's 3-0 home Test sweep over South Africa last year, while Bumrah has claimed 68 scalps in 14 Tests since his debut.